



iTrack™ Canaloplasty to be Featured at the 17th European Glaucoma Society (EGS) Congress in Brussels

Adelaide, Australia, May 28, 2026 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary iTrack™ canaloplasty technology platform will be featured in three poster presentations during the official scientific program of the 17th European Glaucoma Society (EGS) Congress, taking place in Brussels, Belgium, 30 May – 2 June 2026.

Held under the theme "With a Little Help from Our Friends," this year's EGS Congress will spotlight three canaloplasty-themed posters from distinguished glaucoma specialists across Europe and the United States. These presentations will offer in-depth insights into long-term clinical outcomes and real-world performance. A summary of the EGS 2026 posters featuring the iTrack™ canaloplasty technology platform is included below:

Posters

"Results of iTrack Global Data Registry to Support the Role of Canaloplasty for Treatment of Glaucoma"

Karl Mercieca, MD; Leonie Bourauel; Karsten Klabe, MD; Keith Barton, MD; Nathan Kerr, MD

"Ab-Interno Canaloplasty for IOP and Medications Reduction in Uncontrolled and Controlled Glaucoma Eyes"

Karsten Klabe, MD; Keith Barton, MD; Karl Mercieca, MD

"Long-Term Clinical Outcomes of Canaloplasty With the iTrack Microcatheter: Transition From Ab-Externo to Ab-Interno Techniques in a Real-World Cohort"

Julia Agapov, DO, MD

Full session details can be accessed via the EGS Congress program.



All educational content of the EGS Congress is planned by its Scientific Committee. The EGS does not endorse, promote, approve, or recommend the use of any products, devices, or services.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

The iTrack™ Advance canaloplasty device has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.

Indications for Use (USA): The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The ab interno surgical technique is not an on-label indication in the USA.*

** The iTrack™ Advance cutting function (goniotomy) is a Class I 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma.*

Indications for Use (International): The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.



For additional information about the *iTrack™ Advance*, including safety information, please visit: <https://itrack-advance.com>

For media enquiries, please contact:

Kate Hunt: Nova Eye Chief Commercial Officer - khunt@nova-eye.com

Giorgio Pirazzini: GP Communications – giorgio@gpcommunications.eu